Metrogyl 400 (Metronidazole 400mg) stands as a cornerstone in the global antimicrobial arsenal. As a nitroimidazole antibiotic, its primary mechanism involves the inhibition of nucleic acid synthesis by forming nitroso radicals that disrupt the DNA of microbial cells. This specific pharmacological pathway makes it indispensable for treating anaerobic bacterial infections and protozoal infestations.
Years Industry Experience
Global Strategic Clients
Tier-1 Verified Suppliers
Annual Global Sales
Targeting Bacteroides fragilis, Clostridium species, and protozoa like Giardia lamblia. Vital for post-operative prophylaxis.
Direct sourcing from Jiangxi Serum Pharma ensures compliance with GMP, BP, and USP standards for international distribution.
Available in bulk wholesale volumes, optimized for hospital networks, pharmacies, and NGO health initiatives worldwide.
The pharmaceutical market for Metronidazole derivatives is witnessing a CAGR growth of 4.5%, driven by the rising prevalence of gastrointestinal infections and the expansion of healthcare infrastructure in emerging economies. In the B2B sector, the demand for **Metrogyl 400 Tablet** is no longer just about curative care but also about preventative surgical protocols.
Jiangxi Serum Pharma Industries Co., Ltd. is pivoting towards Smart Manufacturing and Bio-Fermentation integration. We are currently implementing:
Jiangxi Serum Pharma Industries Co., Ltd. is a professional supplier of pharmaceutical and nutritional products in China. For nearly 10 years, we have been dedicated to exporting biological products, vaccines, Western medicines, raw materials, intermediates, medical consumables, food additives, and plant extracts, and have accumulated rich industry experience.
Our pharmaceutical products consist of biological products, vaccines, western medicines, raw material, intermediates, medical consumables, with high quality and affordable prices. Serum Pharma will continuously monitor the development of the cutting-edge markets.
We provide more than just wholesale Metrogyl 400 tablets; we offer integrated healthcare solutions. In rural healthcare settings, Metronidazole is a frontline treatment for pelvic inflammatory disease (PID) and aspiration pneumonia. Our supply chain optimization allows for:
Compliance-ready documentation for Ministry of Health (MoH) tenders in Southeast Asia and Latin America.
Expertise in Pre-mix and Bio-Fermentation for niche therapeutic requirements.
Annual sales exceeding $10,000,000 USD backed by robust logistics that maintain API integrity during transit.
The future of Metronidazole lies in Targeted Delivery Systems. Jiangxi Serum Pharma is actively researching sustained-release formulations that minimize gastric side effects while maintaining therapeutic plasma concentrations. We are also expanding our Nutritional Ingredients portfolio, integrating probiotics that can be co-administered with antibiotics to preserve gut microbiome health.
"Our vision is to bridge the gap between high-end pharmaceutical innovation and affordable access in the developing world. Through strategic wholesale Metrogyl 400 distribution, we are fulfilling a critical need in global anti-infective therapy."
— Management Team, Jiangxi Serum Pharma Industries Co., Ltd.